Publicaciones (368) Publicaciones de JOSE LUIS GORRIZ TERUEL

2024

  1. Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus

    Journal of Clinical Medicine, Vol. 13, Núm. 21

  2. Congestion as a crucial factor determining albuminuria in patients with cardiorenal disease

    Clinical Kidney Journal, Vol. 17, Núm. 6

  3. Effect of Avenciguat on Albuminuria in Patients with CKD Two Randomized Placebo-Controlled Trials

    Journal of the American Society of Nephrology, Vol. 35, Núm. 9, pp. 1227-1239

  4. Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD

    Journal of the American Society of Nephrology, Vol. 35, Núm. 10, pp. 1381-1390

  5. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

    Nature Medicine, Vol. 30, Núm. 10, pp. 2849-2856

  6. Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post-hoc analysis of the ROTATE-3 study

    Diabetes, Obesity and Metabolism, Vol. 26, Núm. 2, pp. 576-582

  7. High-sensitivity C-reactive protein and risk of clinical outcomes in patients with acute heart failure

    Scientific Reports, Vol. 14, Núm. 1

  8. Multidisciplinary Delphi consensus on challenges and key factors for an optimal care model in chronic kidney disease

    Nefrologia, Vol. 44, Núm. 5, pp. 678-688

  9. Performance of the Roche Elecsys® IGRA SARS-CoV-2 test for the detection and quantification of virus-reactive T cells in COVID-19-vaccinated immunosuppressed patients and healthy subjects

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 7, pp. 1427-1436

  10. Response to the letter: “Preeclampsia: a relevant chronic kidney disease risk factor frequently and unfortunately forgotten”

    Nefrologia

  11. Risk factors for progression in KDOQI stage 3 Chronic Kidney Disease (PROGRESER study)

    Nefrologia, Vol. 44, Núm. 5, pp. 689-699

  12. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial

    Nature Medicine

  13. Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients

    Nephrology Dialysis Transplantation, Vol. 39, Núm. 4, pp. 618-626

  14. Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action

    Nefrologia , Vol. 44, Núm. 2, pp. 129-138

  15. Urinary Cell Cycle Arrest Biomarkers and Diuretic Efficiency in Acute Heart Failure

    CardioRenal Medicine, Vol. 14, Núm. 1, pp. 261-269

2023

  1. Assessment of filling pressures and fluid overload in heart failure: an updated perspective

    Revista Espanola de Cardiologia, Vol. 76, Núm. 1, pp. 47-57

  2. Cardiorenal benefits of finerenone: protecting kidney and heart

    Annals of Medicine, Vol. 55, Núm. 1, pp. 502-513

  3. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus

    Journal of Clinical Medicine, Vol. 12, Núm. 1

  4. Comments on “Nonvalvular atrial fibrillation in patients undergoing chronic haemodialysis. Should dialysis patients with atrial fibrillation receive oral anticoagulation?”

    Nefrologia

  5. Comments on “Nonvalvular atrial fibrillation in patients undergoing chronic hemodialysis. Should dialysis patients with atrial fibrillation receive oral anticoagulation?”

    Nefrologia